Please login to the form below

Not currently logged in
Email:
Password:

Hospira CEO joins board of Kythera

Michael Ball named director of aesthetic medicine specialist

Kythera Michael BallKythera Biopharmacueticals has appointed Hospira's CEO Michael Ball to the company's board of directors.

Ball has served as CEO at Hospira, creators of the first biosimilar to be launched in the EU, since 2011.

He joined the company following a 16-year stint at Botox developers Allergan, serving as president from 2006. His earlier roles at Allergan included president of pharmaceuticals and president for North America.

This experience in aesthetic products such as Botox will serve him well in his role at Kythera, with the company currently developing ATX-101 as an injectable treatment for the reduction of fat under the chin and around the neck. The drug is currently in phase III development.

"We are thrilled to have him on board,” commented Keith Leonard, Kythera's president and CEO. “His knowledge and perspective will support our mission to bring innovation to the growing area of aesthetic medicine."

2nd October 2013

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics